enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Eli Lilly, Boehringer Share Jardiance Data In Heart ... - AOL

   www.aol.com/news/eli-lilly-boehringer-share...

   In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...

3. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes. [ 29 ] [ 30 ] [ 31 ] It is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to ...

4. Lilly, Boehringer say Jardiance slows kidney disease ... - AOL

   www.aol.com/news/lilly-boehringer-jardiance...

   In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...

5. Biden targets diabetes drug Jardiance, blood thinner Eliquis ...

   www.aol.com/finance/biden-targets-diabetes-drug...

   The diabetes treatments Jardiance from Eli Lilly and Co. and Merck's Januvia made the list, along with Amgen’s autoimmune disease treatment Enbrel. Other drugs include Entresto from Novartis ...

6. Cardiovascular disease - Wikipedia

   en.wikipedia.org/wiki/Cardiovascular_disease

   Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. [3] CVDs constitute a class of diseases that includes: coronary artery diseases (e.g. angina, heart attack), heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease ...

7. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

8. The One Thing Cardiologists Are Begging You to Do to Protect ...

   www.aol.com/one-thing-cardiologists-begging...

   Further, if you're worried about the vaccine causing heart health problems, you can rest easy. Related: These Are the 2 Most Common COVID Symptoms Doctors Are Seeing Right Now

9. Baker Heart and Diabetes Institute - Wikipedia

   en.wikipedia.org/wiki/Baker_Heart_and_Diabetes...

   It contributes to heart failure being a progressive disease, one in which the heart continually gets worse. The device is placed in the heart using a catheter-based system. A thin metal wire made of a special medical-grade alloy tightens up this valve, putting a little ring around it from the outside, which improves the function of the mitral ...